An allergy crisis will occur?
1 to 2 tablets as necessary
(up to 10 tablets a day). Chew until the tablet(s) is (are) dissolved.
Ideally, do not take during mealtimes.
Just 10 to 15 minutes to let
SniZtop® bioactives reaching
the allergens and acting
on the origin of your allergy.
Thanks to SniZtop® rapid effect, you can continue your activities without any allergy symptoms. Red nose & red eyes over!
SniZtop® bioactives are ovomucoïds, a glycoprotein derived from quail egg of a specific quail species. Investigation in quail eggs dates back in Europe to the early 1970's.
Interest in quail eggs in Asia
Quail egg benefits discovery on farmers raising quails (Dr. JC. Truffier)
Subsequent investigations in several human clinical trials (Dr. G. Bruttmann)
In vitro researches
Anti-allergic properties of ovomucoids
STRAGEN proprietary manufacturing process Quail egg benefits into a tablet (GMP standards)
STRAGEN Clinical Study Publication
Food Science & Nutrition
SniZtop® offers all the quail egg benefits in 1 chewable tablet.
SniZtop® acts upstream of the allergic cascade by blocking allergens before they can activate the immune cells and therefore prevents the release of inflammatory mediators such as histamine.
SEE MORE ON VIMEOMarket test performed on 70 French patients to evaluate
their feelings on perennial allergies.
I play tennis and spring is an important season for competitions. As soon as the days get warmer, I can feel my allergic reactions getting stronger, my eyes start to get sore, itchy and watery. I tried SniZtop® when I had a strong allergic reaction and I could feel an instant relief. It’s effective!
Romain, 14 yo - Saint-Etienne, France
SniZtop® has been proven in 2 clinical studies.
More than 300 patients tested SniZtop® and the results are very conclusive.
The efficacy of SniZtop® on the reduction of rhinitis symptoms acutely experienced by subjects upon exposure to a cocktail of common outdoor and indoor allergens has been proven in a randomized, double-blind, crossover, placebo-controlled study (N=43).
Subjects were exposed (by inhalation) to a standardized allergenic challenge followed by the intake of 2 tablets of SniZtop® or placebo.
Measurements were taken every 15 min, for 2 hours.
Objective measurement
of the nasal congestion
(Peak Nasal Inspiratory Flow - PNIF)
Subjective measurement
of nasal & eyes symptoms
(Visual analogue scale (VAS) score)
Adverse Event Analysis
SniZtop® provides allergy relief within 10 to 15 minutes
All bothersome allergy symptoms were significantly reduced.
Subjects' perceived feeling of well-being was highly improved.
SniZtop® efficacy on the alleviation of eczematous lesions, itching sensation and on improvement within the quality of life in patients with Atopic Dermatitis (N=281).
Subjects were divided in 4 groups:
Doses were from 1 to 4 tablets per day, and adjusted to the severity of clinical symptoms and the age of the patient.
The whole observation period lasted 8 weeks with follow up visit every 4 weeks.
Surface of skin affected
SCORAD score
(index dedicated to the diagnosis, treatment, and management
of Atopic Dermatitis)
Itching sensation, sleep disorders,
oedema, redness, erosions
and lichenification
Sniztop® reduces itching sensation in 80% of patients within the first 4 weeks of treatment.
Quality of sleep has been consequently improved in 79% of young children (< 5 years old).